This section will outline ways to navigate various personal experiences during or after cancer treatment.
If you feel we have missed an important issue, please contact us so we can work on adding it.
Learn
- Cancer Types
- Issues Affecting Cancer Patients
- Asbestos and mesothelioma
- Blood clots and cancer
- Bone metastases
- Caregivers
- Chemo-induced nausea and vomiting (CINV)
- Clinical Trials
- Drug approval in Canada
- Drug pricing policy in Canada
- Drug safety in Canada
- Financial cost of cancer
- Genetic testing
- Febrile Neutropenia
- HPV and cancer
- Canadian organizations mark the first annual international HPV awareness day: Give love, not HPV
- HPV vaccine expanded to include ‘at-risk’ boys
- Key points for policy-makers and health professionals
- WHO Information on Human papillomavirus (HPV) and cervical cancer
- Human Papillomavirus and Related Cancers in Canada, Fact Sheet 2010
- Reframing the debate
- WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer
- Insurance and cancer
- LGBTQ+ issues
- Lymphedema
- Medical Cannabis
- Information on Medical Cannabis
- Part One: Why Cannabis Works
- Part Two: Medical Conditions & Products
- Part Three: Accessing Medical Cannabis
- Part Four: Medical Cannabis Myths & Facts
- PDQ Cancer Information Summaries
- Medical Cannabis Infographics
- Medicinal cannabis: Used throughout the ages for medicinal, therapeutic and religious purposes
- Cannabinoids: The chemical components of cannabis
- Potential therapeutic uses of medical cannabis
- Medical cannabis strains
- Cannabis contamination
- Want to learn more about the science of medical cannabis?
- Webinars & Slideshows
- Glossary of terms
- Medical Cannabis “How To”
- Medical Cannabis in the Media
- Patient Stories
- Health Canada Reports Increasing Use Of Cannabis And Cannabis Vaporization
- Canadian Cancer Survivor Network Submission : Task Force on Marijuana Legalization and Regulation
- A Framework for the Legalization and Regulation of Cannabis in Canada
- Information on Medical Cannabis
- Tumour Agnostic Treatments and Companion Diagnostics
- Mental Wellness
- New treatments
- ALECENSARO® (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer
- AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer
- First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada
- Health Canada Approves ERLEADA™* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
- Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma
- Health Canada approves Ipsen’s Somatuline® Autogel® for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)
- Health Canada approves KISQALI™ for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy
- Health Canada approves PERJETA® (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery
- Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
- Health Canada approves TECENTRIQ® (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer
- Health Canada Approves XTANDI® (enzalutamide) – the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
- Lynparza® (olaparib) Receives New Indication for BRCA-Mutated Metastatic Breast Cancer
- Lynparza® (olaparib) tablets receive approval as maintenance therapy treatment for ovarian cancer regardless of BRCA status
- Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma(i)
- Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
- Health Canada Approves RITUXAN® Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia
- Health Canada Approves New Indication for ZYTIGA®* (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer
- Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF® (trifluridine and tipiracil tablets) for metastatic colorectal cancer
- Tagrisso® (osimertinib) receives full Health Canada approval for targeted treatment of non-small cell lung cancer
- Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE™ for the First-Line Treatment of Metastatic Breast Cancer
- Palliative Care
- Prevention
- Research resources
- Wait times in Canada
- Issues Affecting Cancer Survivors
- Survivorship Issues
- Health Data Should Follow Patients
- Anorexia
- Brain Fog
- Cardiovascular Changes
- Deconditioning
- Diabetes
- Disfigurement and Amputation
- Fatigue
- Function and Mobility
- Hair Loss (Alopecia)
- Impotence
- Urinary Incontinence
- Infertility
- Lymphedema
- Mood disorders
- Bone Loss
- Ostomy
- Pain
- Post-Traumatic Stress Disorder (PTSD)
- Secondary Malignancies and Recurrence
- Swallowing and Speech
- Work Productivity
- Personal Experiences When Dealing With Cancer
- Cancer Rehabilitation
- Living Healthy
- Canadian Organizations
- USA Organizations
- Survivorship Issues
- Cancer Centres
- Medicare
- Cancer Months